GLP-1 analogues: historical landmarks, scientific development and mechanisms of action
The advent of GLP-1 analogues embodies a major turning point in the management of type 2 diabetes and obesity. It all began with the discovery of the biological role of the saliva of the Gila monster by Dr John Eng. This breakthrough led to the development of exendin, the first peptide to mimic GLP-1 activity. Some say that the first extraction was carried out under almost artisanal laboratory conditions, before gaining the attention of major pharmaceutical groups. Today’s formulas – such as semaglutide or tirzepatide – are a direct result of this scientific breakthrough, which was soon taken up worldwide.
Among this family’s flagship products are:
Ozempic, Wegovy (semaglutide), Mounjaro, Zepbound (tirzepatide), administered by weekly or daily injection depending on the chosen protocol.
These treatments stimulate the pancreas to produce insulin at mealtime, slow glucagon secretion and slow gastric transit. This concerted action is attracting more and more diabetic patients, sometimes disappointed with previous treatments, who are looking for an alternative with validated efficacy.
Action on glycemia and appetite management contributes to gradual weight reduction while optimizing nutritional control.
Phase III clinical studies reveal a significant improvement in metabolic balance, with a drop in HbA1c in diabetics and a reduction in body weight in those who are overweight. The choice between weekly injections (Wegovy, Zepbound) or daily injections (certain exendins) is tailored to each patient’s profile – the discussion is usually with the general practitioner or diabetologist, sometimes after multidisciplinary consultation in a reference center.
Want to know more? Official scientific references offer detailed insight into these therapeutic solutions.
Clinical efficacy: measured benefits and optimal conditions of use
The performance of GLP-1 analogues is reshaping therapeutic expectations:
The average weight reduction oscillates between 15% and 21% of initial weight over one year with Wegovy or Zepbound, sometimes exceeding this depending on the case, especially in “hyper-responder” profiles. These figures are impressive, but the plateau effect often appears after a few months: behavioral weaning (with nutritional support) is then necessary to hope to maintain weight loss durably.
In diabetics, glycemic control evolves favorably, HbA1c decreases significantly.
The intervention of multidisciplinary teams, combining psychological support, nutritional follow-up and exercise, plays a key role in the lasting stabilization of results. Often, a psychologist or specialized educator is included in the follow-up routine.
Adopting an individual approach, associating doctor, dietician and psychologist, favors quality management. In fact, some patients testify that this support has had a greater impact on their dietary behavior than the medication itself.
The duration of the therapeutic protocol and dosage are personalized according to criteria such as BMI, comorbidities or cardiovascular history, but also according to the patient’s experience and receptiveness to change.
| Indication | Country | Modality | Recommended duration | Reimbursement |
|---|---|---|---|---|
| Obesity (BMI >30 or >27 + comorbidity) | France, United States, Canada | Weekly injection (Wegovy, Zepbound) | 6 to 18 months | Yes, under conditions |
| Diabetes type 2 | European Union, USA | Weekly or daily injection | Infinite (long-term) | Reimbursed depending on country |
| Aesthetic weight loss (off indication) | World | Not recommended | — | Not reimbursed |
Patient profile: assessment of BMI, possible cardiovascular history, and motivation to engage in follow-up
Nutritional support: gradual anchoring of new dietary automatisms, which presupposes a genuine effort on the part of patients – clearly not for everyone
Medical monitoring: adjustments or discontinuation if adverse signals arise, follow-up by pharmacovigilance centers or general practitioners
It’s best to discuss it with a healthcare professional, who will guide the choice of treatment and its follow-up.
Side effects and associated risks: spectrum, frequency and public health issues
The growing interest in GLP-1 analogues is accompanied by increased monitoring of their effects and risks, particularly by pharmacovigilance centers and diabetic patient associations, which regularly relay alerts.
Panorama of observed effects
Common effects:
Nausea, vomiting, intestinal disorders (diarrhea, constipation), abdominal cramps
Some report a transient hair loss
Sensation of lassitude or marked satiety which can, according to testimonials, make eating very unappealing during the first few weeks
Major risks:
Pancreatitis (uncommon, but closely monitored), in which case treatment must be discontinued
Any acute effects must be reported to the pharmacovigilance authorities – ANSM, FDA, but also, the pharmacist remains an essential link in this process.
Hijacked use for purely cosmetic purposes, and circulation on the black market, increase the tension on availability and impact diabetics’ access to these vital medical solutions. In some countries, temporary marketing bans have even been introduced to avoid stock-outs for priority patients. Moreover, insulin shortages are sometimes reported, which raises a real public health concern and puts insurance solidarity back at the heart of the debate.
For any suspected adverse reaction, turn to your pharmacist or doctor without delay. Diabetic patients are invited to report any new or intense effects to pharmacovigilance centers.
Market, regulation, economic issues and disparities in access
The boom in the GLP-1 analog sector is underpinned by scientific innovation and major economic maneuvers. The giants of the field – Novo Nordisk (Denmark) and Eli Lilly (USA) – have to contend with the rise of new competitors, such as AstraZeneca, Roche, Amgen.
Worldwide, the adoption of these anti-obesity and anti-diabetes treatments differs, sometimes markedly:
In Europe, prescribing obeys strict protocols and precise BMI thresholds. However, a number of demographic studies show that there are disparities in treatment by region and age.
In the United States and the United Kingdom, media coverage (the “buzz” generated by certain celebrities) is multiplying demand and testing access arrangements. Unprecedented prevention campaigns around misuse have even emerged on social networks, led by TikTok.
The Chinese, Australian and Canadian markets obey heterogeneous rules, combining regulatory obstacles and pricing differences. Brazil and Japan, meanwhile, are experiencing phases of occasional bans or restrictions.
State of the market: prices, regulations and tensions
| Company | Country | Price per injection (USD) | Access/regulation | Tension/scarcity |
|---|---|---|---|---|
| Novo Nordisk (Wegovy/Ozempic) | Europe, US | 79 to 936 | Strict criteria in EU, more open in US | Periodic breaks |
| Eli Lilly (Mounjaro/Zepbound) | US, Europe | 150 to 800 | Protocol depending on indication, variability | One-off shortages |
| AstraZeneca, Roche, Amgen (in development) | World | — | Subject to testing, limited access | Not marketed |
Pressure on industry: redeployment of production capacity in favor of these new classes, which also explains insulin shortages at times
Inequalities of access: real economic barriers persist, and growing recourse to the parallel market varies greatly according to social coverage or local Health Insurance
It’s up to you to compare the criteria for coverage and reimbursement in force in your country or region – incidentally, a US Senate hearing of Novo Nordisk’s CEO recently rekindled the debate on regulation and pricing.
Medical, social and ethical perspectives: future challenges and expected developments
The widespread arrival of GLP-1 analogues is reshaping the ways in which obesity and diabetes are treated. The move towards precision medicine is evident in the individual adjustment of prescriptions, work on chronic disease prevention and psychological support – it’s no longer unusual to see information campaigns geared towards “body positivity” and self-acceptance promoting fair access to care.
Working on body acceptance, mitigating grossophobia, guaranteeing fair access to therapies: these are central issues, but the ethical question of equity of access remains hotly debated in association networks and public debates.
There are also increasing questions about the medicalization of appearance and the reality of long-term follow-up, not to mention the prevention of detour outside medical protocol. Questions are now also being asked about the societal prospects of personalized medicine: how can we support the transformation of social models around the body and avoid drug resistance linked to prolonged exposure?
Health professionals, patients, associations and vigilance centers are joining forces to anticipate and normalize the irruption of these drugs into everyday life – some patient associations are even launching public information campaigns aimed at pharmacies and care centers.
A number of information campaigns are emerging to support the transition to a more humane approach to care, where technique does not take precedence over the therapeutic relationship, notably on the occasion of prevention events organized by players such as the World Health Organization (WHO) or in conjunction with media such as The Guardian or The Dr Oz Show.
Don’t hesitate to raise your questions in public debates or with leading associations.
